SCHEMBL260397

SCHEMBL260397

CCC1OC(n2cnc3c(Cl)nc(N)nc32)C2OC(C)(C)OC12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.53
PI4K2B Q8TCG2 1/20 0.53
PI4K2A Q9BTU6 1/20 0.53
PI4KB Q9UBF8 1/20 0.53
RXFP1 Q9HBX9 1/20 0.49
NT5E P21589 1/20 0.48
P2RX1 P51575 1/20 0.45
P2RX3 P56373 1/20 0.45
P2RX4 Q99571 1/20 0.45
AMD1 P17707 2/20 0.43
LMNA P02545 3/20 0.43
TP53 P04637 2/20 0.43
ALDH1A1 P00352 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP2C19 P33261 1/20 0.42
SLC29A1 Q99808 3/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA1 P30542 1/20 0.41
HINT1 P49773 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25354403 0.91 PI4KA (0.66) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL280550 0.85 LMNA (0.58) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL18512532 0.85 PI4KA (0.59) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL25354612 0.84 RXFP1 (0.49) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL10118148 0.82 PI4KA (0.60) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL14086537 0.81 ADORA3 (0.56) LMNAADORA3ADORA1
SCHEMBL14111376 0.81 ADORA3 (0.56) LMNAADORA3ADORA1
SCHEMBL17205409 0.80 LMNA (0.54) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL23914964 0.80 LMNA (0.65) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL18493278 0.80 LMNA (0.65) PI4KAPI4K2BPI4K2API4KBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133880-B2 Purine derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2012-03-13 US disclosed
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF PNP, NUDT1, HPRT1 PI4KA 1919/4885PI4K2B 2485/4885PI4K2A 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.